Fulcrum Therapeutics shares are trading lower after HC Wainwright & Co and RBC Capital downgraded the company and lowered their respective price targets on the stock.
Portfolio Pulse from Benzinga Newsdesk
Fulcrum Therapeutics shares declined following downgrades and reduced price targets from HC Wainwright & Co and RBC Capital.
September 13, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Fulcrum Therapeutics shares are trading lower after receiving downgrades and reduced price targets from HC Wainwright & Co and RBC Capital.
The downgrades and reduced price targets from two reputable firms, HC Wainwright & Co and RBC Capital, are likely to negatively impact investor sentiment and lead to a short-term decline in Fulcrum Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100